-
-
-
-
-
-
-
Piper Sandler: 'We Are Naming Capricor Therapeutics (CAPR) As a 2026 Top Pick'
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Halted, News Pending
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Reports In-Line Q3 EPS, offers outlook
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) PT Lowered to $24 at H.C. Wainwright
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

